Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. news
  3. cognitive decline
Show results for
Products
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Cognitive Decline Articles & Analysis

22 news found

Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease

Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease

The current standard of care, hematopoietic stem cell transplantation (HSCT), has been shown to stabilize cognitive decline and significantly improve long-term neurological outcomes when performed prior to symptom onset. ...

ByForge Biologics, Inc.


AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways

AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways

It was previously investigated in a clinical Phase 2a study in Alzheimer’s disease in which blarcamesine resulted in a lower rate of both cognitive and functional ...

ByAriana Pharma


Redox Check-Up

Redox Check-Up

Clinical research activities link OS to several chronic human diseases, such as cardiovascular diseases, cognitive decline, diabetes, premature aging and frailty. The evaluation of the RedOx balance might improve the network of clinical parameters characterizing the patient’s well-being, as part of an growing widespread customization of medicine and with ...

ByH & D S.r.l.


Research from Beacon Biosignals Presented at Alzheimer`s Association International Conference

Research from Beacon Biosignals Presented at Alzheimer`s Association International Conference

Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard electroencephalography (EEG) data to detect electrical disturbances in the brain that may predict cognitive decline and explain variability in disease course for patients with Alzheimer's disease. ...

ByBeacon Biosignals, Inc.


Publications by our customers - current trends

Publications by our customers - current trends

(Neuropsychologia 155, 107825) Alain et al. looked into the causality behind age-related decline in vision, hearing, and touch. In their experiment where visual, auditory, and somatosensory areas were stimulated, older adults showed higher amplitudes of associated primary cortical areas compared to younger adults. ...

ByBESA GmbH


Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. ...

ByAltoida, Inc.


Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. ...

ByAltoida, Inc.


Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

In addition, the data provided indications supporting further exploration of Lomecel-B, particularly the therapeutic potential to slow cognitive decline and improve quality of life in patients with AD. “After meeting the rigorous requirements of the VA, we are pleased to announce the addition of this particular Miami VA site to our ongoing trial,” ...

ByLongeveron, Inc.


Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

In addition, the data provided indications supporting further exploration of Lomecel-B, particularly the therapeutic potential to slow cognitive decline and improve quality of life in patients with AD. “We are pleased and encouraged by the publication of our study in this high-impact journal,” said Geoff Green, CEO of Longeveron. ...

ByLongeveron, Inc.


Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)

Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)

It is now broadly acknowledged that one key step to improving brain health in the overall medical field lies in a readily accessible, non-invasive, precise, and objective diagnostic test for patients suffering from and/or at risk of cognitive decline. Thus, targeted intervention can take place as early as possible, ideally prior to brain damage/memory loss, and ...

ByOptina Diagnostics


£600k grant funding from Innovate UK To validate the NeuroMotor PenTM for screening of dementias and cognitive im-pairment

£600k grant funding from Innovate UK To validate the NeuroMotor PenTM for screening of dementias and cognitive im-pairment

Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, has received £600,000 grant funding from Innovate UK, to optimise and validate the NeuroMotor PenTM (NMP) for screening of dementias and cognitive impairment, over a two-year project. Only around 68% of over 65s, estimated to have dementia have ...

ByManus Neurodynamica


How the brain-eye connection aims to make memory loss a souvenir

How the brain-eye connection aims to make memory loss a souvenir

The health of your brain and your heart are also connected, which means managing cardiovascular risk factors like diabetes, obesity and high blood pressure can also reduce the risk of cognitive decline. The barriers of Alzheimer’s diagnosis One of the biggest obstacles to addressing cognitive decline (including memory ...

ByOptina Diagnostics


Lilly`s donanemab slowed Alzheimer`s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

Lilly`s donanemab slowed Alzheimer`s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found donanemab met its primary endpoint and ...

ByEli Lilly and Company


Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test

Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test

Absence of amyloid plaques is inconsistent with an Alzheimer's disease diagnosis and indicates other causes of cognitive symptoms should be investigated. An intermediate APS (37-57) does not distinguish between the presence or absence of amyloid plaques and indicates further diagnostic evaluation may be needed to assess the underlying cause(s) for the patient's ...

ByC2N Diagnostics


Optina Diagnostics announces a collaborative clinical research study with the Alzheimer Center Amsterdam, Amsterdam UMC

Optina Diagnostics announces a collaborative clinical research study with the Alzheimer Center Amsterdam, Amsterdam UMC

Additionally, results will be evaluated for possible correlations with findings on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), and cognitive performance measurements. “With this special eye scanner, it may be possible that in the future, research and maybe clinical applications can be done quickly and in a very patient-friendly way to diagnose ...

ByOptina Diagnostics


Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients

Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients

“A large proportion of individuals with end-stage renal disease who receive hemodialysis have cognitive impairment, which may be associated with reduced ability for self-care, poor adherence to dietary and fluid restrictions, and poor outcomes,” said Karoly Nikolich, Ph.D., chief executive officer of Alkahest. ...

ByAlkahest, Inc.


Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics

Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics

Alzheimer’s awareness month, Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics, November 6th 2019 Optina Diagnostics Optina Diagnostics, a world leading company in retinal imaging and artificial intelligence with a vision ...

ByOptina Diagnostics


Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease

Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease

Optina Diagnostics’ platform is intended for the detection of likely positron-emission tomography (PET) amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. ...

ByOptina Diagnostics


Why Sleep Deprivation Is a Serious Threat to Firefighters

Why Sleep Deprivation Is a Serious Threat to Firefighters

Contrastingly, studies show that the short-term effects of REM-lacking sleep begin with a decline in cognitive skills. Fixing the issue long-term, Peterson suggests, begins at the core of the problem: shift times. ...

ByTargetSolutions


Computerized Cognition Test Provides Better Assessment than Observation

Computerized Cognition Test Provides Better Assessment than Observation

Research published in the Journal of Alzheimer’s Disease this week suggests healthy older adults are less capable of observing their own cognitive decline over an 18 month period than Cogstate’s computerized brief battery (CBB). The study, conducted by neuropsychologists, also indicated that close family members were unable to perceive ...

ByIOS Press

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Industry Products
  • Medical Industry Software
  • Medical Industry Training
  • Medical Industry Services
  • Medical Industry Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles
  • Medical Industry Books
  • Medical Industry Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT